Manejo de los oligodendrogliomas
DOI:
https://doi.org/10.51437/nj.v24i3.18Abstract
Los oligodendrogliomas son tumores gliales provenientes de los oligodendrocitos. Tienen un comportamiento menos agresivo que el del resto de tumores
pertenecientes a la familia de los gliomas, sin embargo, algunos terminan teniendo un desenlace fatal. En general, son tumores bien diferenciados, difusamente
infiltrantes y pueden evolucionar de oligodendrogliomas de bajo grado a oligodendrogliomas anaplásicos, o pueden ser anaplásicos sin precursores.
Se localizan principalmente en los hemisferios cerebrales, siendo el lóbulo frontal el más afectado en el 50-65% de los casos, seguidos en orden de frecuencia
por el lóbulo temporal, el parietal y el occipital. También se pueden localizar en fosa posterior, ganglios basales, tallo, médula y leptomeninges.
References
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol (Berl). 12 de julio de 2007;114(2):97-109.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (Berl). junio de 2016;131(6):803-20.
Liwnicz BH, Rubinstein LJ. The pathways of extraneural spread in metastasizing gliomas: a report of three cases and critical review of the literature. Hum Pathol. julio de 1979;10(4):453-67.
Maloney PR, Yamaki VN, Kumar R, Johnson D, Hunt C, Jentoft ME, et al. Osteosclerosis secondary to metastatic oligodendroglioma. Rare Tumors [Internet]. 31 de marzo de 2017 [citado 15 de septiembre de 2017];9(1). Disponible en: http://www.pagepress.org/journals/index.php/rt/article/view/6837.
C M, L T, C M. Neurosurgical Management of Gliomas. En: Abujamra AL, editor. Diagnostic Techniques and Surgical Management of Brain Tumors [Internet]. InTech; 2011 [citado 17 de septiembre de 2017]. Disponible en: http://www.intechopen.com/books/diagnostic-techniques-and-surgical-management-
of-brain-tumors/neurosurgical-management-of-gliomas.
Pouratian N, Schiff D. Management of Low-Grade Glioma. Curr Neurol Neurosci Rep. mayo de 2010;10(3):224-31.
Alattar AA, Brandel MG, Hirshman BR, Dong X, Carroll KT, Ali MA, et al. Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. J Neurosurg. 12 de mayo de 2017;1-8.
A Mirza F, Shamim MS. Extent of resection and timing of surgery in adult low grade glioma. JPMA J Pak Med Assoc. junio de 2017;67(6):959-61.
Bonney PA, Boettcher LB, Burks JD, Baker C, Conner AK, Fujii T, et al. Rates of Seizure Freedom after Surgical Resection of Diffuse Low-Grade Gliomas. World Neurosurg. 30 de junio de 2017;
Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315-29.
Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 7 de abril de 2016;374(14):1344-55.
Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. noviembre de 2016;17(11):1521-32.
Hadjipanayis CG, Widhalm G, Stummer W. What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas? Neurosurgery. noviembre de 2015;77(5):663-73.
Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol Off J Am Soc Clin Oncol. 20 de junio de 2006;24(18):2707-14.
van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJB, Bernsen HJJA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European
Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 20 de junio de 2006;24(18):2715-22.
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol Off J Am Soc Clin Oncol. 10 de diciembre de 2009;27(35):5874-80.
Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncol. noviembre de 2016;18(11):1529-37.
Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T. Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol. septiembre de 2006;79(2):153-7.
Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: longterm follow-up. Neuro-Oncol. abril de 2006;8(2):183-8.
Blumenthal DT, Won M, Mehta MP, Curran WJ, Souhami L, Michalski JM, et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J Clin Oncol Off J Am Soc Clin Oncol. 10 de febrero de 2009;27(5):733-9.
Triebels VHJM, Taphoorn MJB, Brandes AA, Menten J, Frenay M, Tosoni A, et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Neurology. 14 de septiembre de 2004;63(5):904-6.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma. N Engl J Med. 20 de febrero de 2014;370(8):709-22.
NCCN Clinical Practice Guidelines in Oncology [Internet]. [citado 18 de septiembre de 2017]. Disponible en: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. noviembre de 1987;21(5):607-14.
Landy HJ, Feun L, Schwade JG, Snodgrass S, Lu Y, Gutman F. Retreatment of intracranial gliomas. South Med J. febrero de 1994;87(2):211-4.
Kostaras X, Cusano F, Kline GA, Roa W, Easaw J. Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline. Curr Oncol Tor Ont. junio de 2014;21(3):e493-503.
Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol. septiembre de 2012;13(9):e375-382.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (Berl). junio de 2016;131(6):803-20.
Liwnicz BH, Rubinstein LJ. The pathways of extraneural spread in metastasizing gliomas: a report of three cases and critical review of the literature. Hum Pathol. julio de 1979;10(4):453-67.
Maloney PR, Yamaki VN, Kumar R, Johnson D, Hunt C, Jentoft ME, et al. Osteosclerosis secondary to metastatic oligodendroglioma. Rare Tumors [Internet]. 31 de marzo de 2017 [citado 15 de septiembre de 2017];9(1). Disponible en: http://www.pagepress.org/journals/index.php/rt/article/view/6837.
C M, L T, C M. Neurosurgical Management of Gliomas. En: Abujamra AL, editor. Diagnostic Techniques and Surgical Management of Brain Tumors [Internet]. InTech; 2011 [citado 17 de septiembre de 2017]. Disponible en: http://www.intechopen.com/books/diagnostic-techniques-and-surgical-management-
of-brain-tumors/neurosurgical-management-of-gliomas.
Pouratian N, Schiff D. Management of Low-Grade Glioma. Curr Neurol Neurosci Rep. mayo de 2010;10(3):224-31.
Alattar AA, Brandel MG, Hirshman BR, Dong X, Carroll KT, Ali MA, et al. Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. J Neurosurg. 12 de mayo de 2017;1-8.
A Mirza F, Shamim MS. Extent of resection and timing of surgery in adult low grade glioma. JPMA J Pak Med Assoc. junio de 2017;67(6):959-61.
Bonney PA, Boettcher LB, Burks JD, Baker C, Conner AK, Fujii T, et al. Rates of Seizure Freedom after Surgical Resection of Diffuse Low-Grade Gliomas. World Neurosurg. 30 de junio de 2017;
Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315-29.
Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 7 de abril de 2016;374(14):1344-55.
Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. noviembre de 2016;17(11):1521-32.
Hadjipanayis CG, Widhalm G, Stummer W. What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas? Neurosurgery. noviembre de 2015;77(5):663-73.
Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol Off J Am Soc Clin Oncol. 20 de junio de 2006;24(18):2707-14.
van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJB, Bernsen HJJA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European
Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 20 de junio de 2006;24(18):2715-22.
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol Off J Am Soc Clin Oncol. 10 de diciembre de 2009;27(35):5874-80.
Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncol. noviembre de 2016;18(11):1529-37.
Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T. Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol. septiembre de 2006;79(2):153-7.
Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: longterm follow-up. Neuro-Oncol. abril de 2006;8(2):183-8.
Blumenthal DT, Won M, Mehta MP, Curran WJ, Souhami L, Michalski JM, et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J Clin Oncol Off J Am Soc Clin Oncol. 10 de febrero de 2009;27(5):733-9.
Triebels VHJM, Taphoorn MJB, Brandes AA, Menten J, Frenay M, Tosoni A, et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Neurology. 14 de septiembre de 2004;63(5):904-6.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma. N Engl J Med. 20 de febrero de 2014;370(8):709-22.
NCCN Clinical Practice Guidelines in Oncology [Internet]. [citado 18 de septiembre de 2017]. Disponible en: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. noviembre de 1987;21(5):607-14.
Landy HJ, Feun L, Schwade JG, Snodgrass S, Lu Y, Gutman F. Retreatment of intracranial gliomas. South Med J. febrero de 1994;87(2):211-4.
Kostaras X, Cusano F, Kline GA, Roa W, Easaw J. Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline. Curr Oncol Tor Ont. junio de 2014;21(3):e493-503.
Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol. septiembre de 2012;13(9):e375-382.
Downloads
Published
2018-06-07
How to Cite
Ayala Villegas, A. C., Ortiz Gómez, L. D., Nieto Rodríguez, J. F., & Preciado Mesa, E. E. (2018). Manejo de los oligodendrogliomas. Español, 24(3), 196–203. https://doi.org/10.51437/nj.v24i3.18
Issue
Section
Artículo de investigación
